Goldman Sachs initiated coverage on ResMed Inc (NYSE:RMD) with a "Buy" rating and a price target of A$48.9, driven by strong growth prospects in its continuous airway pressure (CPAP) therapy segment.
Sleep apnea or other forms of the sleep disorder require an effective CPAP machine to enhance your health and sleep patterns.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback